Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02151409
Recruitment Status : Completed
First Posted : May 30, 2014
Last Update Posted : February 9, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009
Publications of Results:
The first-in-human trial of the humanised monoclonal antibody NNC 0151-0000-0000 blocking the C5a receptor (C5aR). EULAR (European League Against Rheumatism) 2009; Country: Denmark City: Copenhagen